New Era in Allogeneic CAR-T: Genome-Engineered Cell Therapies Delivering on Scale, Durability, & Access
- Exploring multi-edit allogeneic CAR-T engineering strategies, including checkpoint disruption and immune cloaking, designed to enhance persistence and antitumor activity
- Reviewing clinical data supporting durable efficacy, rapid treatment access, and scalable manufacturing across lymphoma and multiple myeloma programs
- Sharing the role of precision genome editing in enabling next-generation off-the-shelf cell therapies with the potential to broaden global patient access